Trump Drug Price Fight Shouldn't Surprise Biotech: Nisen

The transcript discusses Trump's drug pricing policy, highlighting his advocacy for Medicare to negotiate drug prices. It explores the challenges of implementing such policies, including opposition from Congress and the pharma lobby. The potential impact on pharmaceutical innovation is debated, with skepticism about claims that price negotiations would hinder R&D. The role of public policy in funding R&D and the broken drug pricing system in the U.S. are also examined, noting the influence of lobbyists and the lack of regulation in the private sector.

What was the historical context behind the decision not to negotiate drug prices during the George W. Bush administration?

In what ways is the drug pricing system in the United States described as broken?